Powering the Immune System to Transform Lives

Our Pipeline

A Deep, Broad Pipeline to Address Unmet Patient Need

Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world. 

Hepatitis Delta

tobevibart1 + elebsiran

Goal:
Treatment
Phase:
Phase 3,33%

Learn more about our therapeutic focus on Hepatitis Delta

Solid Tumors

VIR-5818 (HER2)2 ± pembrolizumab

Goal:
Treatment
Phase:
Phase 1,75%

VIR-5500 (PSMA)2

Goal:
Treatment
Phase:
Phase 1,75%

VIR-5525 (EGFR)2

Goal:
Treatment
Phase:
Phase 1,25%

Undisclosed PRO-XTEN™ TCE targets3

Goal:
Treatment
Phase:
Pre-clinical,75%

Learn more about our therapeutic focus on Oncology

HIV Cure

Preclinical antibody candidates

Collaborator:
Gates Foundation
Goal:
Treatment
Phase:
Pre-clinical,75%

Learn more about our therapeutic focus on HIV

1 Tobevibart incorporates Xencor’s Xtend™ and other Fc technologies.
2 Masked TCEs licensed from Sanofi.
3 Vir Biotechnology has exclusive rights to the PRO-XTEN™ masking platform for oncology and infectious disease. PRO-XTEN™ is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

HER2: human epidermal growth factor receptor 2; PSMA: prostate-specific membrane antigen; EGFR: epidermal growth factor receptor; TCE: T-cell engager; HIV: human immunodeficiency virus.